Brokerage : Shinhan Securities
Analyst : Minyong Eom, Seokhyeon Yoon
Investment Rating : BUY (Maintained)
Target Price : KRW 570,000 (Downgraded)
Core Momentum : Execution of a new out-licensing deal with GSK significantly eases patent litigation concerns, while clarification of Keytruda SC’s 2% royalty reduces key estimation uncertainties, paving the way for additional multi-partner licensing.
📊 1. [Valuation & Key Financial Metrics]
- Rating & Target Price: BUY (Maintained) & Sector Top Pick / Target Price KRW 570,000 (Downgraded due to multiple adjustments; earnings estimates maintained) (Upside potential of 22.3% based on the January 20, 2026 closing price of KRW 466,000)
- Target Price Downgrade Rationale: Valuation multiples were recalibrated to reflect the lower-than-anticipated 2% royalty rate for Keytruda SC disclosed in Merck’s regulatory filings.
- Market Data: Market Cap KRW 25.74 Trillion / Shares Outstanding 53.5 Million (Floating Shares 79.6%) / 52-Week High KRW 559,000, Low KRW 317,500 / 60-Day Average Trading Value KRW 278.86 Billion / Foreign Ownership 13.9% / Major Shareholders: Soonjae Park and 4 affiliates 20.4%, Inwoo Hyung and 2 affiliates 5.1%
- Annual Financial Forecast (Shinhan Securities Estimates):
- 2025F: Revenue KRW 239.3 Billion, Operating Profit KRW 114.1 Billion (OPM 47.7%), Net Profit (Controlling) KRW 25.0 Billion, PER 967.3x, PBR 81.2x, ROE 8.7%, EV/EBITDA 205.1x
- 2026F: Revenue KRW 579.3 Billion, Operating Profit KRW 342.1 Billion (OPM 59.1%), Net Profit (Controlling) KRW 423.8 Billion, PER 61.2x, PBR 35.9x, ROE 83.0%, EV/EBITDA 73.3x
- 2027F: Revenue KRW 998.7 Billion, Operating Profit KRW 477.3 Billion (OPM 47.8%), Net Profit (Controlling) KRW 608.3 Billion, PER 42.6배, PBR 19.5배, ROE 59.3%, EV/EBITDA 51.5x
🚀 2. [Market Opportunities & Business Outlook]
- GSK Out-Licensing Execution & Low Patent Risk Indication:
- On January 20, finalized a new licensing agreement with GSK, an existing Halozyme partner.
- GSK’s selection of Alteogen after closely evaluating potential patent exposure supports the analyst’s view that the risks of patent invalidation or preliminary injunctions against Alteogen’s SC products are remarkably low.
- Competitive Strength of Non-Exclusive Target Structuring:
- Because Alteogen utilizes non-exclusive target licensing structures, it was able to license GSK’s Jemperli despite having already licensed Merck’s Keytruda for the same PD-1 target.
- Ongoing discussions are progressing with multiple global pharmaceutical companies across complex modalities including bispecifics and ADCs.
- Keytruda SC Terms Confirmed & Future Royalty Economics:
- Disclosure of Merck’s agreement terms confirmed a relatively low 2% royalty rate for Keytruda SC, inducing short-term valuation multiple adjustments while reducing and clarifying key estimation uncertainties.
- According to company guidance, royalties for future licensing agreements signed after Keytruda are expected to track primarily within the mid-single digit (4%–6%) range.
📝 Editor’s Comment (Perspective)
The analyst views Alteogen as a drug delivery platform leader that has recalibrated its valuation (lowering the target price to KRW 570,000) following the disclosure of Keytruda SC’s 2% royalty rate, while significantly easing patent litigation concerns through its landmark agreement with GSK. The overarching perspective prioritizes the reduction of earnings estimation uncertainties, the scalability of its non-exclusive licensing model to secure multiple partners per target class, and the higher mid-single digit (4%–6%) royalty potential of upcoming pipeline deals over short-term multiple compression.
To verify whether this investment thesis progresses as expected, investors should primarily monitor the financial inflows from the GSK deal, commercial prescription ramp for Keytruda SC globally, the execution of new definitive licensing agreements across ADCs and bispecifics under the non-exclusive licensing model, and the actual realization of mid-single digit (4%–6%) royalty terms in future transactions. These developments can be verified through upcoming quarterly earnings releases, official company IR presentations, regulatory filings on DART/KRX, and global partner corporate updates.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
